A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor

What is the purpose of this trial?

The purpose of this study is determine if the triplet combination of ribociclib, everolimus and exemastane is effective in the treatment of locally advanced/metastatic breast cancer following treatment with a CDK 4/6 inhibitor.


Participation Guidelines

Ages: 18 years and older

Gender: Both


Novartis Pharmaceuticals

Dates: 02/02/2017 - 01/01/2018

Last Updated: 02/09/2017

Study HIC#: 1608018178